fluphenazine enanthate (BioDeep_00001868282)
Main id: BioDeep_00000006637
代谢物信息卡片
化学式: C29H38F3N3O2S (549.2636684)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
InChI: InChI=1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3
描述信息
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
同义名列表
2 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:5125
- KEGG: C07955
- KEGGdrug: D00792
- PubChem: 3389
- ChEMBL: CHEMBL1200951
- CAS: 2746-81-8
- PubChem: 10156
- NIKKAJI: J7.903K
- KNApSAcK: 5125
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Elizete M Reis, Jivago Röpke, Alcindo Busanello, Patrícia Reckziegel, Caroline Q Leal, Caroline Wagner, Aline A Boligon, Margareth L Athayde, Roselei Fachinetto. Effect of Hypericum perforatum on different models of movement disorders in rats.
Behavioural pharmacology.
2013 Oct; 24(7):623-7. doi:
10.1097/fbp.0b013e3283656d68. [PMID: 23962987] - J C Levron, R Ropert. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
L'Encephale.
1987 Mar; 13(2):83-7. doi:
. [PMID: 2885172] - B M Cohen, C Waternaux, G Chouinard, B R Sommer, B Jones. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Journal of clinical psychopharmacology.
1985 Dec; 5(6):328-32. doi:
. [PMID: 4066997] - M W Jann, L Ereshefsky, S R Saklad. Clinical pharmacokinetics of the depot antipsychotics.
Clinical pharmacokinetics.
1985 Jul; 10(4):315-33. doi:
10.2165/00003088-198510040-00003. [PMID: 2864156] - A C Altamura, S H Curry, S Montgomery, D H Wiles. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
Psychopharmacology.
1985; 87(1):30-3. doi:
10.1007/bf00431773. [PMID: 3933035] - A C Altamura, R Whelpton, S H Curry. Animal model for investigation of fluphenazine kinetics after administration of long-acting esters.
Biopharmaceutics & drug disposition.
1979 Oct; 1(2):65-72. doi:
10.1002/bdd.2510010204. [PMID: 552863] - J E Groves, M R Mandel. The long-acting phenothiazines.
Archives of general psychiatry.
1975 Jul; 32(7):893-900. doi:
10.1001/archpsyc.1975.01760250085009. [PMID: 239663]